CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 21 enrolled
Drug / intervention
Ramucirumab +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03689855
NCT03689855Phase 2Completed
CompareCT.gov

Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC (RamAtezo-1)

Washington University School of Medicine·interventional·Posted Oct 1, 2018·Updated Jul 30, 2024

In Brief

A Phase 2 clinical trial evaluating Ramucirumab, Atezolizumab, and 2 other interventions for Non-small Cell Lung Cancer and 2 related conditions. Completed, enrolled 21 participants across 1 site.

Detailed Summary

Data suggests that combining ramucirumab with immunotherapy in non-small cell lung cancer (NSCLC) patients who have previously received immune checkpoint blockers (ICBs) may be more effective than traditional therapy. The investigators propose a pilot study to test the combination of ramucirumab and atezolizumab in patients with advanced-stage NSCLC patients previously treated with ICB.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer, Non Small Cell Lung Cancer, NSCLC
CountriesUnited States
CollaboratorsEli Lilly and Company

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedOct 1, 2018
Enrollment StartJun 5, 2019
Primary CompletionJul 16, 2021
Study CompletionApr 22, 2024
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 7.8 years ago

Interventions

Ramucirumabdrug

Ramucirumab is an investigational agent for this trial and will be supplied by Lilly Oncology, free of charge to the patient.

Atezolizumabdrug

The initial dose will be administered over 60 minutes (+/- 15 minutes). If the first infusion is tolerated without infusion-associated events, the second infusion may be delivered over 30 minutes (+/- 10 minutes).

Peripheral blood drawprocedure

-Baseline and Cycle 2 Day 1

Biopsyprocedure

* If archival biopsy tissue not available, participant will undergo biopsy at baseline * When feasible, a repeated tumor biopsy will be obtained between Cycles 2 and 3 after the scheduled CT scan.